



T3D

MINT IT. PRINT IT.

ASX ANNOUNCEMENT

31 July 2026

Appendix 4C and Quarterly Activities Report

The Board of Directors of 333D Ltd (ASX:T3D or “**Company**”) releases its cash flow report (**Appendix 4C**) for the quarter ending 30 June 2026 (“**the quarter**”) and provides an update on activities during the quarter.

QUARTERLY ACTIVITIES REPORT

- **Cash receipts from customers of \$820,670 for the quarter (March 2026 quarter: \$231,702), reflecting an increase in software development services and digital asset management services delivered to customers**
- **FY2026 cash receipts from customers of \$1,701,720, an increase of 69% on FY2025 (\$1,008,331)**
- **Net operating cash outflow of \$250,085 for the quarter (FY2026: outflow of \$117,018), reflecting additional software development costs incurred during the quarter**
- **Completion of the Company’s FY2026 software development program on its digital asset management platform**
- **\$245,730 applied to investing activities during the quarter, comprising the \$149,930 equity investment in Firmus Grid Limited and \$95,800 of capital equipment**
- **Cash and cash equivalents of \$312,018 at 30 June 2026, together with Bitcoin holdings valued at \$185,530 as at 30 July 2026**

Principal Activities

333D Limited operates in digital asset creation, management and monetisation, with a focus on healthcare applications including DICOM-based medical imaging. The Company provides software development services, digital asset management services, 3D content creation and AI-enabled file encoding for use across digital platforms and physical outputs such as 3D printing. There was no change in the nature or scale of the Company’s activities during the quarter.

Artificial intelligence at the centre of the business

FY2026 was the year in which artificial intelligence moved from a supporting technology within 333D’s digital asset platform to a mainstay activity of the Company. The Company now applies AI across three connected pillars, each of which advanced materially during the quarter.

1. **Applied AI** – proprietary clinical software. The Company continues to develop proprietary AI clinical software built on its DICOM digital assets, structured around a multi-phase technical and regulatory framework aligned with the Therapeutic Goods Administration’s regulatory environment for software-based medical devices. During the quarter the development team completed a major model training and evaluation milestone and commenced pre-deployment optimisation and validation activities. Training was

333D Limited

ABN 24 118 159 881

Level 23, Rialto South Tower,
525 Collins Street,
Melbourne VIC 3000 Australia





conducted on a multi-thousand-study dataset of de-identified cone-beam CT (CBCT) scans sourced under the data-sharing arrangement announced on 31 July 2024. The software is being developed for the dental and maxillofacial imaging market, with commercial pathways through both clinical-network integration and standalone software offerings.

2. **AI-enabled digital asset platform.** The Company's revenue-generating platform is itself increasingly an AI product. During the quarter the Company deployed \$95,800 in capital equipment to expand the compute and processing capability underpinning its digital asset management services, enabling higher-volume automated encoding, classification and management of medical imaging and 3D data. This investment supports both existing customer contracts and the training and inference requirements of the Company's own AI development program.
3. **AI infrastructure exposure.** As announced on 9 June 2026, the Company invested \$149,930 in Firmus Grid Limited, a next-generation AI data centre platform backed by NVIDIA which recently completed a US\$505 million capital raise led by Coatue Management. The investment provides 333D shareholders with early, capital-efficient minority exposure to Australian AI infrastructure at a credentialled pre-listing valuation, alongside the Company's in-house development of proprietary AI intellectual property.

The Board views these initiatives as complementary expressions of a single strategic direction, positioning 333D at the intersection of applied AI and AI infrastructure. The Company's longitudinal medical imaging datasets – including data generated through its collaboration partners – are a differentiated input to that strategy, providing the time-series clinical data on which diagnostic AI depends.

Operating and financial review

Cash receipts from customers for the quarter were \$820,670, compared with \$231,702 in the March 2026 quarter. The increase is attributable to an increase in software development services and digital asset management services delivered to the Company's healthcare sector customers during the quarter, together with the timing of billing and collection under those contracts.

For FY2026 as a whole, cash receipts from customers were \$1,701,720, an increase of 69% on FY2025 (\$1,008,331). The Board is pleased with the continued growth in both service lines and considers this to reflect the ongoing scalability of the Company's digital asset management model.

\$A	Q4 FY26	Q3 FY26	FY2026	FY2025
Receipts from customers	820,670	231,702	1,701,720	1,008,331
Net operating cash flow	(250,085)	71,505	(117,018)	70,677
Net investing cash flow	(245,730)	-	(616,230)	-
Net financing cash flow	-	-	970,000	-
Cash at end of period	312,018	807,833	312,018	75,266

Net operating cash flow for the quarter was an outflow of \$250,085, compared with an inflow of \$71,505 in the March 2026 quarter. The movement reflects additional software development costs incurred during the quarter as the Company completed the FY2026 development program



on its digital asset management platform, together with annual corporate and compliance costs. For FY2026 as a whole, the Company recorded a net operating cash outflow of \$117,018 after applying approximately \$1 million to platform and software development during the year, consistent with the budgeted expenditure referred to in the Company's announcement of 16 September 2025.

Software development and digital asset management

The Company continued to invest in the capability and capacity of its digital asset management platform during the quarter. The FY2026 software development program was completed, with additional software development costs incurred in the June quarter to meet customer requirements and to support increased transaction volumes across the platform.

In addition, the Company deployed \$95,800 in capital equipment during the quarter to expand the processing capability underpinning its digital asset management services, as foreshadowed in the Company's *Appendix 4C* for the March 2026 quarter. This equipment supports higher-volume automated encoding, classification and management of medical imaging and 3D data.

Product development

As announced on 9 June 2026, the Company continued to progress its proprietary AI clinical software development program, which is based on the Company's DICOM digital assets and is structured around a multi-phase technical and regulatory framework aligned with the Therapeutic Goods Administration's regulatory environment for software-based medical devices.

During the period the development team completed a model training and evaluation milestone and commenced pre-deployment optimisation and validation activities. Training was conducted on a multi-thousand-study dataset of de-identified cone-beam CT (CBCT) scans sourced under the data-sharing arrangement announced on 31 July 2024. The software is being developed for application in the dental and maxillofacial imaging market. The program remains at a development stage and the Board will update shareholders as it reaches subsequent technical and commercial milestones.

Investment in Firmus Grid Limited

As announced on 9 June 2026, the Company invested \$149,930 in Firmus Grid Limited, a next-generation AI data centre platform, providing the Company with a minority exposure to the AI infrastructure sector on a capital-efficient basis. The investment was funded from existing cash reserves. As stated at the time, the Board considers the investment not to be material to the Company and it does not constitute a change in the nature of the Company's activities.

Summary of expenditure incurred

Total operating expenditure for the quarter was \$1,070,755, comprising:

- Product and operating costs (including software development): \$587,470
- Staff costs: \$20,578
- Administration and corporate costs: \$462,707

The increase in expenditure compared with the March 2026 quarter is principally due to additional software development costs incurred in completing the FY2026 development program, together with annual corporate, audit and compliance costs recognised in the June quarter.

In addition, the Company applied \$245,730 to investing activities during the quarter, being the \$149,930 investment in Firmus Grid Limited and \$95,800 of capital equipment.



Bitcoin treasury

The Company continues to hold Bitcoin as a long-term strategic asset in accordance with its *Bitcoin Treasury Management Policy*. As at 30 July 2026, the market value of the Company's Bitcoin holdings was \$185,530. Together with cash and cash equivalents of \$312,018 reported at Item 5.5 of the *Appendix 4C*, this represents total liquidity of \$497,548. The Company did not acquire or dispose of any Bitcoin during the quarter.

Capital management and funding

The Company held cash and cash equivalents of \$312,018 at 30 June 2026. As disclosed at Item 8 of the *Appendix 4C*, this represents approximately 1.25 quarters of funding measured against the June quarter operating cash outflow. The Board does not consider the June quarter outflow to be representative of the Company's underlying operating position, as it included the completion and settlement of the FY2026 software development program. The Company's responses to the questions at Item 8.6 of the *Appendix 4C* are set out in that document.

Payments to related parties

Pursuant to ASX *Listing Rule 4.7C.3*, payments to related parties and their associates during the quarter totalled \$93,633. This comprised \$21,427 in accounting service fees and \$12,206 in reimbursements for expenses incurred on behalf of the Company to entities related to Director Dr Nigel Finch, and \$60,000 in director's fees paid to Mr John Conidi.

Change of Company Secretary

The Company advises that Ms Catherine O'Connor retired as Company Secretary of 333D Limited effective 31 July 2026. The Board thanks Ms O'Connor for her contribution and service to the Company over her tenure.

The Board is pleased to advise the appointment of Ms Alyn Tai as Company Secretary, effective 31 July 2026. Ms Tai is a Partner at major Australian law firm Thomsons, where she advises boards and executives of ASX-listed entities on corporate governance, continuous disclosure, ASX Listing Rules and Corporations Act compliance, and company secretarial matters, alongside a transactional practice spanning mergers and acquisitions and equity capital markets. She holds a Bachelor of Laws (Honours) from the University of Exeter.

The Board looks forward to the benefit of Ms Tai's governance and listed-company experience as the Company continues to execute its strategy.

Events subsequent to the quarter

Subsequent to the end of the quarter, there were no material events impacting the Company's cash position.

Use of Funds Statement

The Company confirms that the quarter is not included in a period covered by a "use of funds" statement or expenditure program in a prospectus, PDS or information memorandum previously lodged under ASX *Listing Rule 1.1*.

- END -



The release of this announcement was **authorised by the Board of Directors** of the Company.

About 333D Limited

333D Limited is a digital asset technology company specialising in the creation, management and monetisation of digital content, with a particular focus on healthcare applications. The Company's capabilities include DICOM-based medical imaging, 2D and 3D digital content creation, AI-enabled file encoding, and digital asset management solutions. Its technologies enable digital assets to be used across multiple platforms, including physical outputs such as 3D printing.

To find out more about 333D visit 333D.co

For further enquiries please contact:

John Conidi - Executive Chairman
+61 (0) 411 773 101
john@333d.co

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

333D Limited

ABN

26 118 159 881

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows		Current quarter \$A	Year to date (12 months) \$A
1.	Cash flows from operating activities		
1.1	Receipts from customers	820,670	1,701,720
1.2	Payments for		
	(a) research and development	-	-
	(b) product manufacturing and operating costs	-587,470	-1,014,197
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs	-20,578	-99,830
	(f) administration and corporate costs	-462,707	-1,118,485
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	1
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	413,773
1.8	Other (provide details if material)	-	-
1.9	Net cash used in operating activities	-250,085	-117,018
2.	Cash flows from investing activities		
2.1	Payments to acquire:		
	(a) entities	-	-
	(b) equity investment	-149,930	-149,930
	(c) property, plant and equipment	-95,800	-95,800
	(d) investments	-	-370,500
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A	Year to date (12 months) \$A
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash used in investing activities	-245,730	-616,230

3.	Cash flows from financing activities		
3.1	Proceeds from issues of share capital	-	970,000
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from financing activities	-	970,000

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	807,833	75,266
4.2	Net cash from / (used in) operating activities (item 1.9 above)	-250,085	-117,018
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-245,730	-616,230
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	970,000

Consolidated statement of cash flows		Current quarter \$A	Year to date (12 months) \$A
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	312,018	312,018

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A	Previous quarter \$A
5.1	Bank balances	312,018	807,833
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	312,018	807,833

6. Payments to related parties of the entity and their associates

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

Current quarter \$A
93,633
-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

Payments to related parties during the quarter totalled \$93,633. This included \$21,427 accounting service fees paid and \$12,206 in reimbursements for expenses incurred on behalf of the Company to entities related to Director Dr Nigel Finch. This also included \$60,000 director's fees paid to Mr John Conidi.

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

	Total facility amount at quarter end \$A	Amount drawn at quarter end \$A
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-

7.5 **Unused financing facilities available at quarter end** -

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8. Estimated cash available for future operating activities	\$A
8.1 Net cash used in operating activities (Item 1.9)	-250,085
8.2 Cash and cash equivalents at quarter end (Item 4.6)	312,018
8.3 Unused finance facilities available at quarter end (Item 7.5)	-
8.4 Total available funding (Item 8.2 + Item 8.3)	312,018
8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	1.25

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

- Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: No. The net cash outflow from operating activities of \$250,085 for the June 2026 quarter is not expected to continue at that level.

The outflow for the quarter reflects the completion and settlement of the Company's FY2026 software development program on its digital asset management platform, together with annual corporate, audit and compliance costs recognised in the June quarter. The Company applied approximately \$1.0 million to platform and software development during FY2026, consistent with the budgeted expenditure referred to in its announcement of 16 September 2025, and a significant proportion of that expenditure was incurred and paid in the June quarter.

For FY2026 as a whole, the Company recorded a net operating cash outflow of \$117,018, and it recorded positive net operating cash flows in two of the four quarters of the financial year. Cash receipts from customers increased to \$820,670 for the June quarter and to \$1,701,720 for FY2026 (FY2025: \$1,008,331), reflecting increased delivery of software development services and digital asset management services.

With the FY2026 development program now complete, the Company expects software development expenditure to normalise in FY2027 and expects its net operating cash flows to improve relative to the June 2026 quarter.

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?
-

Answer: Yes. The Company has taken, and proposes to take, the following steps:

(a) Research and Development Tax Incentive. The Company has incurred significant eligible research and development expenditure during FY2026 in connection with the development of its digital asset management platform and its clinical software development program. The Company is in the process of preparing its FY2026 registration with AusIndustry and its income tax returns, following which it will lodge its claim under the Research and Development Tax Incentive (**RDTI**). Based on the level of eligible expenditure incurred during FY2026, the Company anticipates that the FY2026 refund will be materially greater than the \$413,773 received in respect of FY2025. The Company expects to receive the refund during the first half of FY2027. The Company received RDTI refunds of \$413,773 in respect of FY2025 and \$101,238 in respect of FY2024. The final amount of the FY2026 refund has not yet been determined and remains subject to the preparation and lodgement of the Company's registration and income tax returns, and to assessment and processing by AusIndustry and the Australian Taxation Office.

(b) Bitcoin holdings. The Company holds Bitcoin with a market value of \$185,530 as at 30 July 2026. While the Company's Bitcoin Treasury Management Policy contemplates a long-term strategic holding, the Bitcoin is held with a regulated exchange and custodian, is liquid, and could be realised by the Board if required to support the Company's working capital requirements.

(c) Equity capital. The Company retains placement capacity under *ASX Listing Rules 7.1 and 7.1A*. In September 2025 the Company completed a placement to institutional and sophisticated investors raising \$1 million (before costs), which the Board considers demonstrates the Company's ability to access equity capital markets. The Company has no current agreement or commitment in place in respect of any further capital raising.

(d) Firmus Grid Limited. The Company holds 1,034 ordinary shares in Firmus Grid Limited, acquired at an average cost of A\$145 per share. While these shares are unlisted and it is not the Board's intention to dispose of this strategic investment, there remains the ability to realise value through secondary market transactions if required. Recent announcements by Firmus indicate that it is undertaking a further capital raising at an issue price of A\$230 per share, which provides support for the current valuation of the investment, although there can be no assurance that any future secondary market sale would occur at that price.

(e) Expenditure management. A substantial proportion of the Company's FY2026 expenditure was discretionary development expenditure. With the FY2026 development program complete, the Board is able to moderate the timing and quantum of further discretionary expenditure to align with available funding.

Having regard to the Company's track record of receiving RDTI refunds in each of the preceding two financial years, its liquid Bitcoin holdings and unlisted equity holdings, its demonstrated access to equity capital markets and its ability to moderate discretionary expenditure, the Board believes that these steps are likely to be

successful. Shareholders should note, however, that the RDTI refund amount and timing are not within the Company's control, and no assurance can be given that any capital raising would be completed on acceptable terms or at all.

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: Yes. The Board expects the Company to be able to continue its operations and to meet its business objectives, on the following basis:


- the Company generates recurring revenue from software development services and digital asset management services, with cash receipts from customers of \$1,701,720 in FY2026, an increase of 69% on FY2025;
- the June 2026 quarter operating cash outflow reflected the completion of the FY2026 software development program and is not expected to recur at that level, with development expenditure expected to reduce in FY2027;
- the Company expects to receive an RDTI refund in respect of FY2026 during the first half of FY2027, having received refunds in each of the two preceding financial years;
- the Company holds liquid Bitcoin with a market value of \$185,530 which could be realised if required;
- the Company retains placement capacity under *ASX Listing Rule 7.1* and *7.1A* and has recently demonstrated access to equity capital markets; and
- a substantial proportion of the Company's expenditure is discretionary and can be moderated to align with available funding.

The Board will continue to monitor the Company's cash position and funding requirements closely and will keep the market informed in accordance with its continuous disclosure obligations.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: **31 July 2026**



Authorised by: **Dr Nigel Finch, Director**
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.